Molecular basis for therapy resistance

Chemoresistance remains the main reason for therapeutic failure in breast cancer as well as most other solid tumours. While gene expression profiles related to prognosis have been developed, so far use of such signatures as well as single markers has been of limited value predicting drug resistance. Novel technologies, in particular with regard to high through‐put sequencing holds great promises for future identification of the key “driver” mechanisms guiding chemosensitivity versus resistance in breast cancer as well as other malignant conditions.